U.K. Value-Based Pricing Negotiations Could Help NICE-Rejected Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Negotiations will start in September 2012 on a value-based pricing approach for new medicines in the U.K., and on a new PPRS scheme for currently marketed drugs, with a new suggestion: oncologics previously rejected by NICE might be reviewed again under the new VBP system.
You may also be interested in...
Local Income Levels, Reference Pricing Key To Fix Pricing Of Patented Drugs In India
A draft circulated by the Department of Pharmaceuticals hopes to provide clarity on pricing of patented drugs in India, but it could lead to heated debate and further complicate pricing strategies for drug makers. The government says it will stick to the core objective to lower health care costs for the masses.
Pressure Builds On U.K. Government To Conclude Value-Based Pricing Deal With Industry
An influential parliamentary committee has called on the U.K. to reveal its plans for value-based pricing by the end of March so that companies, clinicians and patients can adjust to the change, which is expected to start in 2014.
Value-Based Pricing's Slow Progress In U.K. Worries Industry
With eighteen months until the start of a new drug pricing scheme, the slow progress and lack of detail on the U.K.'s value-based pricing (VBP) approach worries industry and suggests transitional arrangements may be necessary.